Fig 3 –

Effect of therapy and AR-V7 status on overall survival. (A) Overall survival by drug class assigned; physicians were more likely to assign a taxane if the patient’s disease was more advanced. (B) Overall survival by drug class after weighting to adjust for physician propensity to administer either drug class influenced by pretherapy patient features, estimating drug-specific survival if cohort was randomized. (C) Overall survival by drug class and AR-V7 status in the context of (B). (D) Interaction multivariable Cox model for (C).

ARSI = androgen receptor signaling inhibitor; CI = confidence interval; HR = hazard ratio; Tx = treatment.